Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 218

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Molecular sampling of prostate cancer: a dilemma for predicting disease progression

Open access
Sboner, Andrea, Demichelis, Francesca, Calza, Stefano, Pawitan, Yudi, Setlur, Sunita R, Hoshida, Yujin, Perner, Sven, Adami, Hans-Olov, Fall, Katja, Mucci, Lorelei A, Kantoff, Philip W, Stampfer, Meir, Andersson, Swen-Olof, Varenhorst, Eberhard, Johansson, Jan-Erik, Gerstein, Mark B, Golub, Todd R, Rubin, Mark A, Andrén, Ove·2010·BMC Medical Genomics

Abstract

Background: Current prostate cancer prognostic models are based on pre-treatment prostate specific antigen (PSA) levels, biopsy Gleason score, and clinical staging but in practice are inadequate to accurately predict disease progression. Hence, we sought to develop a molecular panel for prostate cancer progression by reasoning that molecular profiles might further improve current clinical models. Methods: We analyzed a Swedish Watchful Waiting cohort with up to 30 years of clinical follow up using a novel method for gene expression profiling. This cDNA-mediated annealing, selection, ligation, and extension (DASL) method enabled the use of formalin-fixed paraffin-embedded transurethral resection of prostate (TURP) samples taken at the time of the initial diagnosis. We determined the expression profiles of 6100 genes for 281 men divided in two extreme groups: men who died of prostate cancer and men who survived more than 10 years without metastases (lethals and indolents, respectively). Several statistical and machine learning models using clinical and molecular features were evaluated for their ability to distinguish lethal from indolent cases. Results: Surprisingly, none of the predictive models using molecular profiles significantly improved over models using clinical variables only. Additional computational analysis confirmed that molecular heterogeneity within both the lethal and indolent classes is widespread in prostate cancer as compared to other types of tumors. Conclusions: The determination of the molecularly dominant tumor nodule may be limited by sampling at time of initial diagnosis, may not be present at time of initial diagnosis, or may occur as the disease progresses making the development of molecular biomarkers for prostate cancer progression challenging.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1755-8794-3-8

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 218

Metadata

Authors
Sboner, A., Demichelis, F., Calza, S., Pawitan, Y., Setlur, S. R., Hoshida, Y., Perner, S., Adami, H.-O., Fall, K., Mucci, L. A., Kantoff, P. W., Stampfer, M., Andersson, S.-O., Varenhorst, E., Johansson, J.-E., Gerstein, M. B., Golub, T. R., Rubin, M. A., & Andrén, O.
Venue
BMC Medical Genomics
Published
2010-03-16
Volume
3
Issue
1
ISSN
1755-8794
OpenAlex
W2151834630
Cited by
218
References
6
FWCI
12.79
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular sampling of prostate cancer: a dilemma for predicting disease progression. https://app.cochat.ai/papers/10.1186/1755-8794-3-8
The paper
Sboner, A., Demichelis, F., Calza, S., Pawitan, Y., Setlur, S. R., Hoshida, Y., Perner, S., Adami, H.-O., Fall, K., Mucci, L. A., Kantoff, P. W., Stampfer, M., Andersson, S.-O., Varenhorst, E., Johansson, J.-E., Gerstein, M. B., Golub, T. R., Rubin, M. A., & Andrén, O. (2010). Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Medical Genomics. https://doi.org/10.1186/1755-8794-3-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.